ArticleInterventional radiology (Higashimatsuyama-shi (Japan)2026
Innovation of a Repeatable Microcatheter-accessible Port (ReMAP): Initial Clinical Results Evaluating Feasibility in the Treatment of Hepatocellular Carcinoma.
Article in Interventional radiology (Higashimatsuyama-shi (Japan), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: This study aimed to evaluate the feasibility of the Repeatable Microcatheter-accessible Port (ReMAP™) system in initial clinical experiences. Material and Methods: Eighteen patients with advanced hepatocellular carcinoma underwent ReMAP™ implantation. The 3.3-Fr catheter tip was positioned in the hepatic, gastroduodenal, or splenic artery, with the side hole located in the common or proper hepatic artery. The 6-Fr proximal end of the catheter was connected to the ReMAP™ device, implanted subcutaneously in the front thigh. A specialized 17-G cannulated needle was used to puncture the ReMAP™ system, allowing insertion of a microcatheter and guidewire, which exited via the side hole and were advanced into the targeted hepatic branches. Results: ReMAP™ implantation was successful in all cases. A total of 85 treatment sessions using microcatheters inserted via the ReMAP™ system were performed. All sessions successfully facilitated selective arterial infusion chemotherapy (75 sessions) and selective transarterial chemoembolization (10 sessions). During the treatment period (mean duration: 4.6 months), complications occurred in three cases (18%), including hepatic arterial occlusion, dislocation of the indwelling catheter, and biloma. Conclusions: Locoregional treatments using the ReMAP™ system are feasible for patients with advanced hepatocellular carcinoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.